Abstract 661P
Background
CY-101 is a synthetic peptide that inhibits the oncogenic Wnt/β-catenin pathway by activating Axin2 and has a pore-forming membranolytic effect on cancer cells that triggers a tumor-specific immune response. Here, we report findings from a phase I/IIa trial evaluating intratumoral (IT) administration of CY-101 monotherapy and in combination with pembrolizumab in patients (pts) with heavily pretreated advanced solid tumors.
Methods
Eligible pts received biweekly (Q2W) IT injections with CY-101 into 1-3 accessible metastatic lesion(s). The primary endpoint was safety and tolerability, with anti-tumor and immunomodulatory activity as secondary objectives. Dose-escalation (2, 8, and 20 mg) followed a ‘3+3 design’ with a 6-week dose-limiting toxicity (DLT) observation period. The recommended dose for further development (R2PD) was explored across three expansion cohorts: A) CY-101 Q2W monotherapy, B) CY-101 plus pembrolizumab 400 mg Q6W, and C) CY-101 Q2W monotherapy in intrahepatic lesions. Response assessment was performed every 8 weeks.
Results
No DLTs were observed in the dose escalation part. The R2PD was defined at 20 mg. In the dose-expansion phase, 45 pts were enrolled among the 3 cohorts A (n=18), B (n=15), and C (n=12). Common grade 1-2 treatment-related adverse events (TRAE) included pain at the injection site (63.6%), fatigue (20.1%), pyrexia (11.4%) and injection site reaction (9.1%). One grade 3 TRAE, due to pain related to IT administration (2.2%), was noted. Histopathologic examination of post-treatment biopsies revealed enlarged necrotic areas and tumor infiltrating lymphocytes in 70%. Across tumor types, the disease control rate was 31%, with 36% having an ongoing response beyond six months. Abscopal partial responses were seen in three pts (2 monotherapy, 1 combination). Notably, among six pts with adrenocortical carcinoma (monotherapy), a disease control rate of 50% (n = 3/6) was observed, with durable responses (> 6 months) in two pts. Both pts expressed β-catenin (IHC) and had somatic mutations in the Wnt/β-catenin pathway (WES).
Conclusions
CY-101 is well tolerated at the RP2D of 20 mg and demonstrated early signs of antitumor activity, especially in tumors with dysregulated Wnt/β-catenin signaling.
Clinical trial identification
NCT04260529; Release date: 05-02-2020.
Editorial acknowledgement
Legal entity responsible for the study
Cytovation AS.
Funding
Cytovation ASA.
Disclosure
S. Champiat: Non-Financial Interests, Institutional, Invited Speaker: Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Genmab, Janssen, Merck, MSD, Novartis, Roche, Servier, Takeda; Non-Financial Interests, Institutional, Principal Investigator: AbbVie, Amgen, Boehringen Ingelheim, Bolt, Biotherapeutics, Centessa Pharmaceuticals, Cytovation, Eisai, GSK, Imcheck Therapeutics, Immunocore, Molecular Partners Ag, MSD, Ose Immunotherapeutics, Pierre Fabre, Replimune, Roche, Sanofi Aventis, Seagen, Sotio AS, Transgene; Non-Financial Interests, Institutional, Advisory Board: Acces Trial, Alderaan Biotechnology, Amgen, AstraZeneca, Avacta, BeiGene, BioNTech, Celanese, Domain Therapeutics, Ellipses Pharma, Genmab, Harpoon therapeutics, Immunicom, Inc., Mariana Oncology, Mima Health, Nanobiotix, Nextcure, Oncovita, Pierre Fabre, Seagen, Takeda, Tatum Bioscience, Tollys, UltraHuman8, UltraHuman8. V. Moreno Garcia: Financial Interests, Personal, Advisory Board: BMS, Janssen, Roche, Basilea, Bayer, AstraZeneca; Financial Interests, Personal, Full or part-time Employment: START; Financial Interests, Institutional, Local PI, AbbVie, AceaBio, Adaptimmune, ADC Therapeutics, Aduro, Agenus, Amcure, Amgen, Astellas, AstraZeneca Bayer BeiGene BioInvent International AB, BMS, Boehringer, Boheringer, Boston, Celgene, Daiichi Sankyo, Debiopharm, Eisai, e-Terapeutics, Exelisis, Forma Therapeutics, Genmab, GSK, Harpoon, Hutchison, Immutep, Incyte, Inovio, Iovance, Janssen, Kyowa Kirin, Lilly, Loxo, MedSir, Menarini, Merck, Merus, Millennium, MSD, Nanobiotix, Nektar, Novartis, Odonate Therapeutics, Pfizer, PharmaMar, Principia, PsiOxus, Puma, Regeneron, Rigontec, Roche, Sanofi, Sierra Oncology, Synthon, Taiho, Takeda, Tesaro, Transgene, Turning Point Therapeutics, Upshersmith: Multiple. F. Opdam: Non-Financial Interests, Principal Investigator: GSK, Int1B3, AstraZeneca, Cytovation, Relay, Taiho, Roche, Merus, Boehringer ingelheim, Crescendo, Pierre Fabre, Lilly, RevMed, Incyte. H. Gelderblom: Financial Interests, Institutional, Local PI: Deciphera, Cytovation; Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim, AmMax Bio, Debiopharm, Abbisko. M. Chaney: Financial Interests, Personal, Full or part-time Employment: Merck and Co., Inc; Financial Interests, Personal, Stocks/Shares: Merck and Co., Inc; Non-Financial Interests, Member: ASCO, AACR. L. Prestegarden: Financial Interests, Personal, Full or part-time Employment: Cytovation. All other authors have declared no conflicts of interest.
Resources from the same session
683TiP - A phase I study of PARP inhibitor (niraparib) plus HSP90 inhibitor (pimitespib) in solid tumors: The NiraPim (EPOC2102) study
Presenter: Hiromichi Nakajima
Session: Poster session 01
684TiP - A phase I, open-label, multicenter, dose escalation and expansion study of HM97662 (EZH1/2 dual inhibitor) as a single agent in patients with advanced or metastatic solid tumors
Presenter: Bhumsuk Keam
Session: Poster session 01
685TiP - A phase I, multicenter trial (“KinLET”) of [177Lu]Lu-edotreotide for treatment of somatostatin receptor positive solid tumors or lymphoma, in patients two to less than 18 years of age
Presenter: Maria Cristina Mata Fernandez
Session: Poster session 01
687TiP - A phase I, first in human study of TORL-4-500 in patients with advanced cancer
Presenter: Jonathan Goldman
Session: Poster session 01
688TiP - Phase I dose escalation trial to evaluate safety and preliminary efficacy of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors
Presenter: Xihui Hu
Session: Poster session 01
689TiP - A phase I/IIa trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors
Presenter: Vaia Florou
Session: Poster session 01
690TiP - HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
Presenter: Thomas Powles
Session: Poster session 01
691TiP - PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Presenter: Alison Schram
Session: Poster session 01
722P - Long-term patient-reported outcomes (PROs) with atezolizumab (atezo) + bevacizumab (bev) and chemotherapy (CT) for metastatic, persistent or recurrent cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase III trial
Presenter: Laurence Gladieff
Session: Poster session 01